RELATED PRODUCTS NOT AVAILABLE
true
Support
Singapore (Greater Asia Head Office)
+65 6664 2700
bd_sea@bd.com
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
Address
2 International Business Park Road, #08-08 The Strategy, Singapore 609930
BD Phoenix™ M50 Instrument
Delivering performance, connectivity and functionality required by clinical microbiology laboratories
- Overview
- Applications
- Products & Accessories
- EIFU & Resources
false
Trusted performance
The BD Phoenix™ system provides on-panel doubling dilutions and built-in detection resistance, including CPO, MRSA, mecA, VRSA, VRE, ESBL, HLAR, and iMLSb*.
Ease of use
The system requires no reagent additions post inoculation and few supplemental tests for final result determination, while utilizing leak-resistant, room-temperature panel storage.
Scalability
The instrument is compact and stackable, allowing for increased testing volumes by doubling capacity within the same footprint.
Advanced data management
The BD EpiCenter™ data management system interfaces with the BD Phoenix™ M50 and provides intuitive, on-demand antibiogram generation and flexible reporting options.
Dual growth detection technology
The BD Phoenix™ M50 instrument determines growth using both an oxidation-reduction indicator and turbidity growth detection to help provide both rapid and accurate susceptibility results.
True doubling dilutions
The BD Phoenix™ system utilizes on-panel doubling dilutions of antimicrobial concentrations for determination of MIC results.
Delayed growth algorithm
The BD Phoenix™ M50 instrument employs a delayed growth algorithm that may defer reporting for slow-growing organisms until additional instrument readings are collected. This feature enables an accurate determination of growth or no-growth, providing additional assurance that results are accurate.
Resistance detection
The BD Phoenix™ system provides on-panel doubling dilutions of antimicrobials and built-in detection of resistance, including CPO, MRSA, mecA, VRSA, VRE, ESBL, HLAR, and iMLSb*. *Depending on BD Phoenix™ panel type and organism identification.
Robust, customizable data management
The BD EpiCenter™ data management system offers the BDXpert system, which implements CLSI breakpoints and SIR interpretations. BD EpiCARE™ is an optional extension of the BD EpiCenter™ system that gives users the ability to define customized rules and actions to ensure compliance for the reporting of microbiology data that may be specific to their organization.
Modular and scalable
The BD Phoenix™ M50 instrument offers a compact and stackable design (up to two instruments) that allows for increased testing volumes by doubling capacity within the same footprint.
Ease of use
The system requires minimal maintenance, no reagent additions post inoculation and few supplemental tests for final result determination, and utilizes leak-resistant, room-temperature panel storage.
Automated inoculation preparation
The BD Phoenix™ AP automated inoculation preparation instrument may help to reduce sample preparation workflow burdens, reducing total hands-on time per sample by 50% compared to manual BD Phoenix™ preparation and by an average of 20% compared to selected competitive products. 1-2
- The BD Phoenix™ M50 system instrument offers identification-only panels and combination ID/AST panels, using 51 wells for identification substrates.
- The system can provide rapid identification of most clinically significant Gram-negative and Gram- positive bacteria, as well as yeast.
- The BD Phoenix™ M50 system offers 85 wells for antimicrobial dilutions on standard AST-only panels and combination ID/AST panels, and 136 wells on the BD Phoenix™ Emerge™ panel.
- The instrument can provide rapid susceptibility results for most clinically significant Gram-negative and Gram-positive bacteria.
- The BD Phoenix™ M50 system panels test for several resistance markers*such as**:
- Gram-positive bacteria
- HLAR—High Level Aminoglycoside Resistant Enterococcus
- iMLSb—Inducible Clindamycin Resistance
- MRSA—based on Oxacillin Interpretation with Staphylococcus species
- mecA – detection of mecA-medicated resistance in Staphylococcus aureus
- BL- Staphylococcus ß-Lactamase (Nitrocefin based test)
- VRSA—Vancomycin-Resistant Staphylococcus Aureus
- VRE—based on Vancomycin interpretation
- Gram-negative bacteria
- CPO—Carbapenemase Producing Organism
- ESBL—offered on Gram-negative panels and requires no additional disc diffusion or E-Test confirmation.
- Gram-positive bacteria
* Depending on BD Phoenix™ panel type and organism identification
- The BD Phoenix™ CPO detect test, available on certain BD Phoenix™ Gram-negative panels, provides information, including Ambler classification, to help guide clinicians in their treatment decisions.
- This test is available in two-panel configurations that allow microbiology labs to test for CPOs as part of routine susceptibility testing on BD Phoenix™ panels:
- 2-well configuration—provides detection of Carbapenemase-producing organisms in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii
- 9-well configuration—provides detection of carbapenemase-producing organisms and Ambler classification (A, B or D) in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii
- The BD Phoenix™ CPO detect test is currently the only phenotypic test on an automated AST system that provides CPO detection and Ambler classification.
- On average, the BD Phoenix™ CPO detect test detects and classifies CPOs from isolated colonies within 6 to 11 hours.**
**BD internal studies—data on file
true
Literature
BD's collection of literature on industry and on our offerings gives you information you can use to continue striving for excellence.
Learn more
true
false
Notes
- Junkins A, et al. Comparison of BD Phoenix™ AP Workflow with Vitek 2. J. Clin. Microbiol. 2010. 48 (5): 1929-1931. Study was supported by grants from BD Diagnostic Systems.
- Jungkind D, et al. Workflow evaluation of the BD Phoenix™ AP Compared to the MicroScan Walkaway overnight system for identification and susceptibility testing of bacteria. As presented at the 110th General Meeting of the American Society of Microbiology. May 2010. Study was supported by grants from BD Diagnostic Systems.
true